乳腺癌预后相关分子生物标记物的研究进展  

Research Progress of Prognosis Related Molecular Biomarkers of Breast Cancer

作　　者：滕晓飞[1] TENG Xiao-fei(Binzhou Medical College Affiliated Hospital,Binzhou Shandong 25660)

机构地区：[1]滨州医学院附属医院,山东滨州256600

出　　处：《世界最新医学信息文摘》2018年第20期36-37,共2页World Latest Medicine Information Electronic Version

摘　　要：乳腺癌是目前女性肿瘤性疾病中发病率最高的肿瘤,严重威胁女性患者的身体健康及生命安全。经治疗后,乳腺癌患者预后状况的判断是乳腺癌临床治疗中的难题之一。为了能准确判断乳腺癌患者的预后情况,及时调整后续治疗方案,探究乳腺癌预后相关分子生物标记物对乳腺癌患者的个体化综合治疗具有重要的意义。Breast cancer has the highest incidence among female cancers at present, which seriously threatens health and life safety of female patients. After treatment, prognosis judgement of breast cancer patients is one of difficult problems in clinical treatment of breast cancer. To predict prognosis of breast cancer patients accurately, adjust followup treatment plan timely, and explore prognostic related molecular biomarkers of breast cancer is of great significance for individualized comprehensive treatment of breast cancer patients.

关 键 词：乳腺癌 预后指标 分子生物标记物 

分 类 号：R737.9[医药卫生—肿瘤]